PROFESSIONAL EDITION

The largest community of pharma leaders

Regulatory Affairs

      NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA

      PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the...

      Epirium Bio Appoints Alexander Casdin, Reneo Capital Management Founder, as Chief Financial Officer

      SAN DIEGO--(BUSINESS WIRE)--Epirium Bio, Inc., a clinical-stage biopharmaceutical company pursuing novel and clinically significant therapeutic approaches for neuromuscular, neurodegenerative and mitochondrial disorders, today announced...

      Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS® (ravulizumab-cwvz) with Significantly Reduced Infusion Time

      BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the U.S. Food and Drug Administration (FDA) has approved ULTOMIRIS® (ravulizumab-cwvz) 100 mg/mL formulation for the treatment...

      Recent Articles